v21 (Simcyp)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Simcyp v21
$Predicted dissolution profile, fraction absorbed, portal vein fraction, and bioavailability versus time for felodipine after in vitro‐in vivo correlation in Simcyp <t>V21.</t>$
V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/software+compound+library+simcyp+v21/v21/pmc10272307-97-18-18
Average 90 stars, based on 1 article reviews

v21 - by Bioz Stars, 2026-11

90/100 stars

Images

1) Product Images from "Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug"

Article Title: Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

Journal: CPT: Pharmacometrics & Systems Pharmacology

doi: 10.1002/psp4.12954

$Predicted dissolution profile, fraction absorbed, portal vein fraction, and bioavailability versus time for felodipine after in vitro‐in vivo correlation in Simcyp V21.$
Figure Legend Snippet: Predicted dissolution profile, fraction absorbed, portal vein fraction, and bioavailability versus time for felodipine after in vitro‐in vivo correlation in Simcyp V21.

Techniques Used: Dissolution, In Vitro, In Vivo

other:

Article Title: 2024 Annual Meeting American College of Clinical Pharmacology®.
Article Snippet: For alprazolam PBPK model, the default compound file in Simcyp v23 was used.

Article Title: Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration.
Article Snippet: However, the predictive performance of the Leniolisib PBPK model appears to be improved using Simcyp V21 compared to those predicted values using Simcyp V15, and the Leniolisib PK profiles were better captured by using Simcyp V21.

Article Title: Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates
Article Snippet: References for Simcyp v21 default compound files 17-19 Supplement 5.

Article Title: Evaluation of the Drug–Drug Interaction Potential of Cannabidiol Against UGT2B7-Mediated Morphine Metabolism Using Physiologically Based Pharmacokinetic Modeling
Article Snippet: Table S2: Key physiochemical and system specific input parameters for the development of physiologically based pharmacokinetic model for cannabidiol using Simcyp v23.

Article Title: 2024 Annual Meeting American College of Clinical Pharmacology®.
Article Snippet: Description of Methods and Materials: Physiologically-based pharmacokinetic models for adult healthy subjects were developed using physicochemical and physiological parameters of atenolol and escitalopram using the Simcyp v23.

Permeability:

Article Title: A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide.
Article Snippet: A bottom-up physiologically based pharmacokinetic (PBPK) model was developed to predict the pharmacokinetics of loperamide, a substrate for multidrug resistance 1 (Mdr1) encoded P-glycoprotein (P-gp), in wild-type dogs (WT) and dogs that are homozygous for a base-pair deletion in the Mdr1 gene encoding for P-gp (Mu, Δ-Mdr1).. In vitro-to-in vivo extrapolation (IVIVE) techniques were employed where in vitro data describing loperamide absorption, distribution, metabolism, and elimination (ADME) were extrapolated to in vivo dose exposure predictions.. Importantly, by applying system parameters extrapolated from other breeds and published information on Collie-specific physiology, for the first time, a breed-specific whole-body PBPK model for the Collie was developed.

Analysis:

Article Title: Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration.
Article Snippet: .. For example, applicant’s PBPK model of Leniolisib (JOENJA, approved for marketing by the FDA on March 24, 2023) used Simcyp V15 in prediction, while Simcyp V21 was used in the FDA reviewer’s analysis. .. However, the predictive performance of the Leniolisib PBPK model appears to be improved using Simcyp V21 compared to those predicted values using Simcyp V15, and the Leniolisib PK profiles were better captured by using Simcyp V21.

Clinical Proteomics:

Article Title: Utility of Physiologically Based Pharmacokinetic Modeling to Investigate the Impact of Physiological Changes of Pregnancy and Cancer on Oncology Drug Pharmacokinetics
Article Snippet: .. In the cancer population model (Simcyp V21), a 15% decrease in plasma albumin level and a 100% increase in AGP levels compared to healthy subjects is incorporated [ ]. ..

Review